All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

19

2023 to 2026

Breakthrough

3

Accelerated

3

Priority review

10

Orphan

13

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202362
202421
202511
202633

19 approvals

Newest first. Hover a badge for what it means.

  • Klygefa (Gefurulimab) · Alexion PharmNov 13, 2026
    Original approval · BLA 761488NovelOrphan

    To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

  • Juvmo (Tavapadon) · AbbvieSep 25, 2026
    Original approval · NDA 220415NovelApproval letter

    To treat Parkinson's disease in adults

  • Isembyld (Apitegromab-Mstn) · Scholar Rock INCSep 11, 2026
    Original approval · BLA 761463NovelPriority reviewOrphanApproval letter

    To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment

  • Tauklarify (Florquinitau F-18) · Cerveau LantheusAug 13, 2026
    Original approval · NDA 220496NovelApproval letter

    To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology

  • Orzeyful (Oveporexton) · Takeda Pharms USAAug 5, 2026
    Original approval · NDA 220860NovelPriority reviewOrphanApproval letter

    To treat narcolepsy type 1

  • Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026
    Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

  • Subvenite (Lamotrigine) · Owp PharmsSep 16, 2025
    Original approval · NDA 218879Approval letter
  • Imaavy (Nipocalimab-Aahu) · Janssen BiotechApr 29, 2025
    Original approval · BLA 761430NovelPriority reviewOrphanApproval letter

    To treat generalized myasthenia gravis

  • Kisunla (Donanemab-Azbt) · Eli Lilly COJul 2, 2024
    Original approval · BLA 761248NovelBreakthrough therapyPriority reviewApproval letter

    To treat Alzheimer's disease

  • Vigafyde (Vigabatrin) · Pyros PharmsJun 17, 2024
    Original approval · NDA 217684OrphanApproval letter
  • Duvyzat (Givinostat Hydrochloride) · Italfarmaco SpaMar 21, 2024
    Original approval · NDA 217865NovelPriority reviewOrphanApproval letter

    To treat Duchenne muscular dystrophy in individuals aged 6 years and older

  • Wainua (Autoinjector) (Eplontersen Sodium) · Astrazeneca AbDec 21, 2023
    Original approval · NDA 217388NovelOrphanApproval letter

    To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis

  • Agamree (Vamorolone) · Catalyst PharmsOct 26, 2023
    Original approval · NDA 215239NovelOrphanApproval letter

    To treat Duchenne muscular dystrophy

  • Zilbrysq (Zilucoplan Sodium) · Ucb INCOct 17, 2023
    Original approval · NDA 216834NovelOrphanApproval letter

    To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive

  • Rystiggo (Rozanolixizumab-Noli) · Ucb INCJun 26, 2023
    Original approval · BLA 761286NovelPriority reviewOrphanApproval letter

    To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive

  • Qalsody (Tofersen) · Biogen MaApr 25, 2023
    Original approval · NDA 215887NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation

  • Zavzpret (Zavegepant Hydrochloride) · PfizerMar 9, 2023
    Original approval · NDA 216386NovelApproval letter

    To treat migraine

  • Skyclarys (Omaveloxolone) · Biogen USFeb 28, 2023
    Original approval · NDA 216718NovelPriority reviewOrphanApproval letter

    To treat Friedrich's ataxia

  • Leqembi (Lecanemab-Irmb) · Eisai INCJan 6, 2023
    Original approval · BLA 761269NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat Alzheimer's disease

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.